Table 1.
Randomized phase III trials with outcome data in patients receiving moderate hypofractionation radiotherapy directed at an intact prostate
| Study Center | Patients | Median Follow-up (years) | Technique | Regimen | Outcome | Late Toxicity |
|---|---|---|---|---|---|---|
| Australia [11] | 217 | 7.5 | 2D/3DCRT | 55 Gy/20 fx vs. 64 Gy/32 fx | Phoenix definition 7.5 yr FFBF 53% vs. 34% (p < .05) | GU symptoms favor HFX at 4 yrs HR |
| ASTRO definition 44% vs. 44% | 1.58 (p < .05) | |||||
| No difference in late GI | ||||||
| Fox Chase Cancer Center [14] | 303 | 5.7 | IMRT | 70.2 Gy/26 fx vs. 76 Gy/38 fx | 5 yr BCF 23% vs. 21% (NS) | Gr ≥ 3 GI 2% vs. 2% |
| Gr ≥ 3 GU 4% vs. 3% | ||||||
| MD Anderson [16,17] | 204 | 4.6 efficacy 6.0 toxicity | IMRT | 72 Gy/30 fx vs. 75.6 Gy/42 fx | ASTRO definition 5 yr FFBF 96% vs. 92% | Gr ≥ 3 GI 2% vs. 1% |
| Gr ≥ 3 GU 1% vs. 0% | ||||||
| Ontario [13] | 936 | 5.7 | 3DCRT | 52.5 Gy/20 fx vs. 66 Gy/33 fx | 5 yr BCF 60% vs 53% | Gr ≥ 3 GI/GU toxicity equal (3.2%) |
| Italy [15,19] | 168 | 5.8 | 3DCRT | 62 Gy/20 fx vs. 80 Gy/40 fx | Phoenix definition 5 yr FFBF 85% vs. 79% (p = .065) | Gr ≥ 3 GI 1% vs. 0% |
| Gr ≥ 3 GU 1% vs. 2% |
FFBF = freedom from biochemical failure, BCF = Biochemical or clinical failure, HFX = hypofractionated.